Articles published by EQRx

EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination

December 02, 2021

From EQRx

Via Business Wire

EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference

November 29, 2021

From EQRx

Via Business Wire

EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

November 22, 2021

From EQRx

Via Business Wire

EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

November 18, 2021

From EQRx

Via Business Wire

Tickers EVO

EQRx Launches “Remaking Medicine: On The Record” Investor Video Series

November 16, 2021

From EQRx

Via Business Wire

EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

October 19, 2021

From EQRx

Via Business Wire

EQRx Appoints Kathy Giusti to Board of Directors

September 27, 2021

From EQRx

Via Business Wire

EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021

September 17, 2021

From EQRx

Via Business Wire

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC

September 13, 2021

From EQRx

Via Business Wire

EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

September 07, 2021

From EQRx

Via Business Wire

EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer

August 18, 2021

From EQRx

Via Business Wire

EQRx Announces Formation of Mission Advisory Board

July 20, 2021

From EQRx

Via Business Wire

EQRx Appoints Carlos Garcia-Echeverria, Ph.D., as Chief of Rx Creation

July 01, 2021

From EQRx

Via Business Wire

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

June 24, 2021

From EQRx

Via Business Wire

Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer

May 28, 2021

From EQRx

Via Business Wire

Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

May 19, 2021

From EQRx

Via Business Wire

EQRx Appoints Jami Rubin as Chief Financial Officer and Kent Rogers as Chief Customer Officer

April 19, 2021

From EQRx

Via Business Wire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.